Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
$60 millionfunding for manufacturing of NVX-CoV2373
- 10 million doses to be delivered to
JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund up to
“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of
As part of the contract,
About the JPEO-CRBND
NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. A Phase 1 clinical trial of NVX‑CoV2373 initiated in
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
Statements herein relating to the future of
Source: Novavax, Inc.